Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This paper examines reported symptoms, nonsmoking rates, and medication use among 1018 smokers using varenicline in a randomized trial comparing three forms of behavioral support for smoking cessation (phone, web, or phone + web). One month after beginning varenicline, 168 people (17%) had discontinued the medication. Most (53%) quit due to side-effects and other symptoms. The most common side-effect among all users was nausea (reported by 57% of users). At one month post medication initiation, those not taking varenicline were more likely to report smoking than those who continued the medication (57% vs. 16%, p<.001). Women reported more symptoms but did not discontinue medication at higher rates. Participants who received any telephone counseling (n=681) were less likely to discontinue their medication than those with web support only (15% vs. 21%, p<.01). Counseling may improve tolerance of this medication and reduce the rate of discontinuation due to side-effects. (149 words)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 2×
“…demonstrated superior efficacy for maintaining abstinence from smoking compared with both placebo and bupropion, with continuous abstinence rates ranging from 28% to 44% at 12 weeks and 21% to 30% at 24 weeks (Gonzales et al., 2006; Jorenby et al., 2006; Nides et al., 2006; Oncken et al., 2006).”
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 1×
“…demonstrated superior efficacy for maintaining abstinence from smoking compared with both placebo and bupropion, with continuous abstinence rates ranging from 28% to 44% at 12 weeks and 21% to 30% at 24 weeks (Gonzales et al., 2006; Jorenby et al., 2006; Nides et al., 2006; Oncken et al., 2006).”
Effects of abstinence from tobacco: Valid symptoms and time course
Hughes, J. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701188919 · Cited by 801 · cited 1×
“They were asked if they had experienced a range of symptoms in the last month that included probable varenicline side effects and common nicotine abstinence or withdrawal effects (Hughes, 2007; see Table 2).”
Nides, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1561 · Cited by 390
Oncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184
Cited by
Telephone counselling for smoking cessation
Stead, L. F., Hartmann-Boyce, J., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002850.pub3 · Cited by 1,003
Combined pharmacotherapy and behavioural interventions for smoking cessation
Stead, L. F., Koilpillai, P., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008286.pub3 · Cited by 829
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Hartmann-Boyce, J., Hong, B., Livingstone-Banks, J., Wheat, H., & Fanshawe, T. R. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009670.pub4 · Cited by 186
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub4 · Cited by 46
Fix, B. V., Hyland, A., Rivard, C., McNeill, A., Fong, G. T., Borland, R., Hammond, D., & Cummings, K. M. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8010222 · Cited by 35
“A previous report indicated that adverse events, which can lead to discontinuation, are commonly reported among varenicline users [23].”
Background
Metadata
- Authors
- Halperin, A. C., McAfee, T. A., Jack, L. M., Catz, S. L., McClure, J. B., Deprey, T. M., Richards, J., Zbikowski, S. M., & Swan, G. E.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 36
- Issue
- 4
- Pages
- 428-434
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W2075412708
- Cited by
- 52
- References
- 7
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.